



## PRESS RELEASE

### AB SCIENCE ANNOUNCES THE COMPLETION OF SETTLEMENT AND DELIVERY OF ITS LATEST CAPITAL INCREASE OF 5.0 MILLION EUROS

Paris, October 9, 2024, 8.30am CET

AB Science SA (the “ **Company** ” or “ **AB Science** ”, Euronext – FR0010557264 – AB) announced on September 30, 2024 a capital increase of €5.0 million subscribed by European qualified investors. AB Science announces today that it has completed the settlement and delivery of this capital increase.

The capitalization table of AB Science is now as follows:

Shareholders	Before the capital increase			After the capital increase (before exercising the warrants)			After the capital increase and exercise of the warrant		
	Number of shares <sup>(1)</sup>	%	Diluted base <sup>(2)</sup>	Number of shares <sup>(1)</sup>	%	Diluted base <sup>(2)</sup>	Number of shares <sup>(1)</sup>	%	Diluted base <sup>(2)</sup>
A. Moussy	7.058.069	11.92%	23.18%	7.058.069	10.93%	21.70%	7.058.069	10.52%	21.07%
AMY SAS <sup>(3)</sup>	12,273,000	20.72%	16.93%	12,273,000	19.00%	15.85%	12,273,000	18.29%	15.39%
<b>Subtotal concert A. Moussy</b>	19.331.069	32.64%	40.12%	19.331.069	29.93%	37.55%	19.331.069	28.81%	36.45%
Other investors members of the concert	1,796,473	3.03%	8.45%	1,796,473	2.78%	7.91%	1,796,473	2.68%	7.68%
Actions in the pact	382.010	0.65%	6.64%	382.010	0.59%	6.22%	382.010	0.57%	6.04%
Actions outside the pact	1,414,463	2.39%	1.80%	1,414,463	2.19%	1.69%	1,414,463	2.11%	1.64%
<b>Total concert</b>	21.127.542	35.68%	48.56%	21.127.542	32.71%	45.45%	21.127.542	31.49%	44.13%
Other investors	38.093.161	64.32%	51.44%	43,461,886	67.29%	54.55%	45.967.291	68.51%	55.87%
<b>Total</b>	<b>59.220.703</b>	<b>100.00%</b>	<b>100.00%</b>	<b>64,589,428</b>	<b>100.00%</b>	<b>100.00%</b>	<b>67.094.833</b>	<b>100.00%</b>	<b>100.00%</b>

<sup>(1)</sup> All classes of shares are affected. The number of ordinary shares amounts to 52,425,569 before the capital increase, 57,594,294 after the capital increase (but before exercise of the warrants), and 60,299,699 after the capital increase and exercise of the warrants.

<sup>(2)</sup> The diluted basis takes into account the exercise of all instruments giving access to the capital, the definitive allocation of all free shares and the conversion of all preferred shares into ordinary shares (aiming for the highest theoretical dilution).

<sup>(3)</sup> AMY SAS is a company controlled by A. Moussy.

None of the investors participating in the transaction exceeds the threshold of 5% of the Company's share capital or voting rights. To the Company's knowledge, no shareholder with the exception of A. Moussy and AMY SAS exceeds the threshold of 5% of the Company's share capital or voting rights.

#### **About masitinib**

Masitinib is a novel orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, essential cells of immunity, by inhibiting a limited number of kinases. Due to its unique mode of action, masitinib can be developed in a large number of pathologies, in oncology, in inflammatory diseases, and certain diseases of the central nervous system. In oncology, through its immunotherapy activity, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglial cells and therefore through its inhibitory effect on the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with certain inflammatory and central nervous system pathologies.

#### **About AB8939**

AB8939 is a next-generation synthetic microtubule destabilizer. Preclinical data show that AB8939 exhibits strong anticancer activity, with the notable advantage over standard microtubule-targeted chemotherapies of being able to overcome drug resistance mediated by P-glycoprotein ( Pgp ) and myeloperoxidase (MPO). The development of drug resistance often limits the clinical efficacy of microtubule-targeted chemotherapies (e.g., taxanes and vinca alkaloids ); AB8939 therefore has strong potential for development in a wide range of oncology indications.

#### **About AB Science**

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development, and marketing of protein kinase inhibitors (PKIs), a class of targeted proteins whose action is decisive in cell signaling. Our programs only target pathologies with high medical need, often fatal with a low survival rate, rare, or resistant to a first line of treatment. AB Science has developed its own portfolio of molecules and AB Science's flagship molecule, masitinib, has already been registered in veterinary medicine and is being developed in humans in oncology, neurodegenerative diseases and inflammatory diseases. The Company is headquartered in Paris and is listed on Euronext Paris ( Ticker : AB).

More information about the Company on the website: [www.ab-science.com](http://www.ab-science.com)

#### **Warning**

In accordance with Article L. 411-1 of the Monetary and Financial Code and the applicable regulatory provisions, no prospectus will be published or approved by the Financial Markets Authority.

With regard to the Member States of the European Economic Area, no action has been undertaken or will be undertaken to permit a public offer of the securities covered by this press release requiring the publication of a prospectus (pursuant to Article 3 of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017) in any of the Member States.

This press release and the information contained herein do not constitute an offer to subscribe for or purchase, or a solicitation of an order to purchase or subscribe for, the New Shares in the United States of America or in any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration under the US Securities Act or an exemption from registration under the US Securities Act . AB Science does not intend to make a public offering of the New Shares in the United States of America or in any other jurisdiction.

The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons into whose possession this press release comes must inform themselves of any local restrictions and comply with them.

The information contained in this document may be modified without notice. This information contains forward-looking statements, which are not guarantees of future performance. These statements are based on

Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Canada, Australia or Japan.

the current expectations and beliefs of AB Science's management team and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. AB Science and its affiliates, directors, officers, employees, advisors or agents do not undertake any commitment and are not obligated to publish updates to any forward-looking statement or to revise any forward-looking statement.

**For any further information, please contact:**

**AB Science**

Financial communication and press relations

[investors@ab-science.com](mailto:investors@ab-science.com)